6
March 2011 Laboratory Focus www.bioscienceworld.ca
APPoinTMenTs fer numerous benefits to patients throughout the world.
Theralase Technologies Inc. announces the appointment of Dr. Arkady Mandel as chief scientific officer. Dr. Mandel earned his designation as a medical doctor from the Moscow State Medical University in 1978. His medical residency included internships in: dermatology, infectious diseases, urology and venereal diseases at the Central Research Institute of Dermatology and Venerology in 1980, followed by a Ph.D. from the same institution in 1982. Dr. Mandel was then awarded in recognition of his scientific knowledge, original research, publications and extensive contributions to the field of clinical medicine the highest academic research degree in science, that of a Doctor of Science. Dr. Mandel’s Doctor of Science accreditation majored in: biochemistry, microbiology, immunology, biophysics, and photobiology, and was awarded jointly from the Academy of Sciences and the U.S.S.R. Ministry of Public Health in 1989. He is also one of the key founders of the therapeutic use of lasers in dermatology and other areas of clinical medicine, as well as the originator and developer of phototherapy methods that of-
James C. Mullen has been named as Patheon’s chief executive officer, effective immediately.
Mr. Mullen has also been appointed a director of Patheon’s Board of Directors. Ramsey Frank, Patheon’s chairman stated, “The Board of Directors is very pleased that Jim Mullen will be joining Patheon. Mr. Mullen’s extensive pharmaceuti-
Delivering Today’s Innovations for the Science of TomorrowTM global suppliers for a myriad of research areas!
Protox Therapeutics Inc. announces the appointment of William Rohn and Amit Sobti to the company’s board of directors. Rohn has over 30 years of experience as a senior executive in the pharmaceutical and biotech industry. He retired in January of 2005 from the position of chief operating officer at Biogen-Idec, and played an instrumental role in the $6.8 billion merger of IDEC Pharmaceuticals and Biogen Inc. Prior to serving as COO of the combined company, Bill was the president and chief operating officer of IDEC Pharmaceuticals where he helped transform IDEC from a small research organization into a very successful, biotechnology company. Rohn prior to joining IDEC spent approximately 25 years in the pharmaceutical sector in a variety of commercial operating roles of increasing responsibilities at Abbott Laboratories, Bristol-Myers Squibb Co., and Adria Laboratories (now part of Pfizer). In addition to his role at Protox, he serves on the Board of Directors of Cerus Corporation, Intellikine, Cebix Inc., and the La Jolla Institute of Allergy and Immunology. Amit Sobti is a principal with Warburg Pincus where he focuses on investments in health-
Consolidate and SAVETM
1,000’s of top
with CEDARLANE
Contact us today at tech@cedarlanelabs.com to find the right reagent for you!
Toll Free... In CANADA: 1-800-268-5058
CEDARLANE
®
www.cedarlanelabs.com
4410 Paletta Court, Burlington, ON L7L 5R2 ph: (289) 288-0001, fax: (289) 288-0020 e-mail: general@cedarlanelabs.com
Reply card #4409
McGill quarter.indd 1
cal manufacturing background and proven track record of driving growth and profitability give us confidence that, under his leadership, Patheon will be able to realize its full potential as an industry leader.” Mr. Mullen was most recently with Biogen Idec, Inc., where he held the position of CEO and president for 10 years. Biogen Idec was formed from the merger, led by Mr. Mullen, of Biogen, Inc. and Idec Pharmaceuticals. Prior to the merger, Mr. Mullen was the CEO and president of Biogen, Inc. from 2000 to 2002, and chairman, CEO and president until 2003. Prior to that, Mr. Mullen held various operating positions at Biogen, including vice president, Operations; and several manufacturing and engineering positions over a nine-year period at SmithKline Beckman, Inc. In addition, Mr. Mullen’s 30-year career includes extensive experience in pharmaceutical and biotech manufacturing, engineering, sales, marketing, mergers and acquisitions. His breadth of industry experience includes biotechnology, pharmaceuticals and specialty chemicals. Mr. Mullen holds a Bachelor of Science in Chemical Engineering from Rensselaer Polytechnic Institute, and a Master of Business Administration from Villanova University.
4/26/2010 12:56:28 PM
care. Prior to joining Warburg Pincus, he worked at Rhône Capital, a mid-market private equity firm, and at Merrill Lynch in the Mergers & Acquisitions group. Sobti received an A.B. in Business Economics and an A.B. in Computer Science from Brown University. In addition to Protox, Amit also serves on the Board of Directors of ReSearch Pharmaceutical Services, Inc. Afexa Life Sciences Inc., announces that Tracey Ramsay has agreed to join the company as chief marketing officer and senior
vice president Sales. Ms. Ramsay will serve on Afexa’s executive leadership team, and will report directly to the chairman and CEO. Before joining Afexa, Ms. Ramsay held positions as vice president of Sales, vice president Marketing and general manager within large multi-national pharmaceutical and healthcare companies. Her strategic and operational management skills have contributed to the development of organizational structures that have realized increased market share for products having complex regulatory requirements. Stewart Davis has been appointed to the role of chief operating officer at Healthscreen Solutions IncDavis has over 30 years of experience in the technology industry and in areas of business including finance, sales and marketing, operations, technology development and executive roles of chairman, CEO and president. Healthscreen also announces that Ms. Teresa Brzozowski, Heathscreen’s current chief operating officer and Ms. Anastasia Chodarcewicz, Heathscreen’s chief financial officer, will be leaving the Company, with both completing their transitions in the coming months. The company also expects to fill the roles of chief financial officer as well as a new role of chief information officer within the next few months.
